

Session	ID number	Title	Name	middle name	Surname
Session 1 - Population and disease registries and epidemiology - Monday June 17, 13:15-14:30 hrs	24163	Survival of ALS patients has increased over time: results from a long-standing register.	Rosario		Vasta
Session 1 - Population and disease registries and epidemiology - Monday June 17, 13:15-14:30 hrs	24205	Increased incidence of motor neuron disease in Sweden: a population-based study during 2002-2021	Sofia		Imrell
Session 1 - Population and disease registries and epidemiology - Monday June 17, 13:15-14:30 hrs	24255	Epidemiology of Amyotrophic Lateral Sclerosis in Catalonia (Spain): 2015-2020	Sergio		Vidal Notari
Session 1 - Population and disease registries and epidemiology - Monday June 17, 13:15-14:30 hrs	24295	Amyotrophic lateral sclerosis caused by the C9orf72 expansion in Norway – prevalence, ancestry, clinical and demographic variables	Helle		Høyer
Session 1 - Population and disease registries and epidemiology - Monday June 17, 13:15-14:30 hrs	24305	A population-based disease mapping of ALS incidence in the Republic of Ireland from 1995 to 2022	Eanna		Mac Domhnaill
Session 2 - Clinical - Monday June 17, 15:00-16:15 hrs	24082	Single-cell transcriptomics reveal the presence of clonally expanding T cells in ALS	Zhenzhen		Chen
Session 2 - Clinical - Monday June 17, 15:00-16:15 hrs	24212	Glymphatic dysfunction occurs across clinical phenotypes of motor neuron disease	Edoardo Gioia		Spinelli
Session 2 - Clinical - Monday June 17, 15:00-16:15 hrs	24246	Brain metabolic features of FUS-ALS: a 2-[18F]FDG-PET study	Antonio		Canosa
Session 2 - Clinical - Monday June 17, 15:00-16:15 hrs	24310	Sex Differences in Amyotrophic Lateral Sclerosis Survival and Progression: A Multidimensional Analysis	Maurizio		Grassano
Session 2 - Clinical - Monday June 17, 15:00-16:15 hrs	24344	Neurofilament content of patient sensory skin axons reflects ALS progression	Julian		Grosskreutz
Session 2 - Clinical - Monday June 17, 15:00-16:15 hrs	24086	Understanding How Cognitive and Behavioural Impairments Affect the Mental Capacity to Make Treatment Decisions in ALS.	Milena		Contreras
Session 3 - Pre-symptomatic changes and imaging - Tuesday June 18, 08:30-9:45 hrs	24327	A comparison of frameworks for identifying cognitive and behavioural impairment in pre-symptomatic ALS	Caroline		McHutchison
Session 3 - Pre-symptomatic changes and imaging - Tuesday June 18, 08:30-9:45 hrs	24111	ECAS correlation with metabolic alterations on FDG-PET imaging in ALS patients	Linn		Oijerstedt
Session 3 - Pre-symptomatic changes and imaging - Tuesday June 18, 08:30-9:45 hrs	24356	QSM-detected iron accumulation in the cerebellar gray matter selectively predicts executive dysfunction in non-demented ALS patients	Claudia		Morelli
Session 3 - Pre-symptomatic changes and imaging - Tuesday June 18, 08:30-9:45 hrs	24057	Cognitive endophenotypes and C9orf72 in familial ALS: a longitudinal study	Colm		Peelo
Session 4 - Genetics - Tuesday June 18, 10:15-11:15 hrs	24091	Multicomic analysis to identify the genetic basis of amyotrophic lateral sclerosis	Calum		Harvey
Session 4 - Genetics - Tuesday June 18, 10:15-11:15 hrs	24020	Plasma extracellular vesicle Tau and TDP-43 as diagnostic biomarkers in FTD and ALS	Anja		Schneider
Session 4 - Genetics - Tuesday June 18, 10:15-11:15 hrs	24321	Using Irish Clan Genomics to Interrogate the Biological Overlap between Amyotrophic Lateral Sclerosis and Neuropsychiatric Disorders	Clara		O'Donoghue
Session 4 - Genetics - Tuesday June 18, 10:15-11:15 hrs	24198	Genome-wide screen for genetic modifiers in ALS progression	Ramona		Zwamborn
Session 4 - Genetics - Tuesday June 18, 10:15-11:15 hrs	24325	The shared ancestry between the C9orf72 hexanucleotide repeat expansion and intermediate-length alleles using haplotype sharing trees and HAPTK	Osma		Rautila
Session 5 - Clinical trials and biomarkers - Tuesday June 18, 14:00-15:15 hrs.	24074	Identification of proteomic clusters in the CSF of sporadic ALS patients	Laura		Tzeplaeff
Session 5 - Clinical trials and biomarkers - Tuesday June 18, 14:00-15:15 hrs.	24401	Combined rescue of STMN2 and UNCT3A mis-splicing in ALS using a novel therapeutic approach	Puja		Mehta
Session 5 - Clinical trials and biomarkers - Tuesday June 18, 14:00-15:15 hrs.	24032	Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis – a longitudinal multicenter study	Thomas		Meyer
Session 5 - Clinical trials and biomarkers - Tuesday June 18, 14:00-15:15 hrs.	24189	Using ALS patient-derived astrocytes to identify patient stratification biomarkers in response to a promising multi-target drug	Raquel		Rua Martins
Session 5 - Clinical trials and biomarkers - Tuesday June 18, 14:00-15:15 hrs.	24071	Skin innervation across ALS clinical stages: new biomarkers of disease progression and survival	Raffaele		Dubbioso
Session 5 - Clinical trials and biomarkers - Tuesday June 18, 14:00-15:15 hrs.	24154	Longitudinal analysis of T cells responses in amyotrophic lateral sclerosis	Salmaz		Yazdani
Session 6 - Biomarkers, basic and translational science - Wednesday June 19, 09:00-10:15 hrs	24081	Stress granules and oxidation drive TDP-43 demixing in the cytoplasm	Jik		Nijssen
Session 6 - Biomarkers, basic and translational science - Wednesday June 19, 09:00-10:15 hrs	24211	Differential pathways of astrocyte toxicity in sporadic ALS	Katie		Bowden
Session 6 - Biomarkers, basic and translational science - Wednesday June 19, 09:00-10:15 hrs	24337	Investigating the metabolic crosstalk between senescent lymphocytes and microglia from patients with ALS	Victoria		Tsang
Session 6 - Biomarkers, basic and translational science - Wednesday June 19, 09:00-10:15 hrs	24027	ALS toxic gain-of-function mechanisms, but not C9orf72 haploinsufficiency impairs the autophagy pathway in C9orf72 ALS/FTD iPSC-derived motor neurons.	Jimmy		Beckers
Session 6 - Biomarkers, basic and translational science - Wednesday June 19, 09:00-10:15 hrs	24041	Targeting EGN2/PHD1 protects motor neurons and normalizes the astrocytic interferon response.	Christine		Germeys
Session 6 - Biomarkers, basic and translational science - Wednesday June 19, 09:00-10:15 hrs	24332	Exploring Metabolic Pathways in ALS: TDP-43, Mitochondria, and Ferroptosis Interplay	Miriam		Ceron Codorniu
Session 7 - Cellular and molecular biology - Wednesday June 19, 13:30-14:45 hrs	24059	(GR)400 and (PR)400 knock-in mice show a conserved neuroprotective role of an extracellular matrix signature in CSALS/FTD	Carmelo		Milioto
Session 7 - Cellular and molecular biology - Wednesday June 19, 13:30-14:45 hrs	24288	C-myc dysregulation contributes to glia-to-neuron miscommunication in Amyotrophic Lateral Sclerosis and Frontotemporal dementia	Manuela		Basso
Session 7 - Cellular and molecular biology - Wednesday June 19, 13:30-14:45 hrs	24012	ATBK1 variant causes autophagolysosomal and motoneuron pathology without neuroinflammation in mice	David		Brenner
Session 7 - Cellular and molecular biology - Wednesday June 19, 13:30-14:45 hrs	24053	Organelleomics: AI-driven deep organellar phenotyping of human neurons	Lena		Molitor
Session 7 - Cellular and molecular biology - Wednesday June 19, 13:30-14:45 hrs	24062	Modelling ALS caused by KIF5A mutations in patient-derived motor neurons	Isabel		Loss
Session 7 - Cellular and molecular biology - Wednesday June 19, 13:30-14:45 hrs	24018	The homeoprotein transcription factor ENGRAILED-1 allows for spinal α-Motoneurons protection and repair	Alain		Prochiantz